MORIMOTO Satoshi    Department   School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine    Position   Associate Professor
Article types	Review article
Language	English
Peer review	Peer reviewed
Presence of invitation	Invited paper
Title	Critical appraisal and pooled analysis of telmisartan alone or in combination with hydrochlorothiazide for achieving blood pressure goals.
Journal	Formal name：Integrated blood pressure control Abbreviation：Integr Blood Press Control ISSN code：11787104/11787104
Domestic / Foregin	Foregin
Volume, Issue, Page	3,pp.73-9
Author and coauthor	Morimoto Satoshi†*, Takahashi Nobuyuki, Morita Tatsuyori, Someya Kazunori, Toyoda Nagaoki, Iwasaka Toshiji
Authorship	Lead author,Corresponding author
Publication date	2010
Summary	Rigid control of blood pressure (BP) is essential to prevent cardiovascular disease. However, only about 40% of hypertensive patients undergoing pharmacological intervention with a single agent achieve their BP goals in contemporary clinical practice. Combined therapy using currently available agents is effective in maximizing treatment outcome, although it raises medical costs and decreases the drug compliance rate. To overcome such negative consequences, a combination tablet containing an angiotensin II receptor blocker (ARB) with a small dose of hydrochlorothiazide (HCTZ) is now available on the international market, including Japan. This article briefly describes the unique properties of telmisartan, a highly selective ARB for the angiotensin II type 1 receptor, including its long-acting characteristics and recent prospective multicenter randomized clinical trials, followed by a description of a newly-introduced combination tablet in Japan, which contains telmisartan and HCTZ. This article also reviews its safety and efficacy based on currently available evidence. Finally, evidence comparing telmisartan/HCTZ with other combination therapies is presented.
DOI	10.2147/ibpc.s9325
PMID	21949623